Spyridon P. Basourakos

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

Likun Li, Styliani Karanika, Guang Yang et al. · Science Signaling · 2017 · 293 citations · Full text

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

Bo Liu, Wenhui Wu, Likun Li et al. · Clinical Cancer Research · 2017 · 105 citations · Full text

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer

Jody V. Vykoukal, Johannes F. Fahrmann, Justin R. Gregg et al. · Nature Communications · 2020 · 79 citations · Full text

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models

Yong Luo, Abul Kalam Azad, Styliani Karanika et al. · International Journal of Cancer · 2017 · 45 citations · Full text

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men

Spyridon P. Basourakos, Roman Gulati, Randy Vince et al. · NEJM Evidence · 2022 · 40 citations · Full text